# Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support

> **NCT00050401** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 500 (—)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** MERREM I.V. 2g as a 3 hour infusion every 8 hours
- **DRUG:** vancomycin I.V. 1 g every 12 hours
- **DRUG:** tobramycin I.V. 5 mg/kg every 24 hours
- **DRUG:** MERREM I.V. 1g as a 30 minute infusion every 8 hours
- **DRUG:** MERREM I.V. 500 mg as a 3 hour infusion every 8 hours

## Key facts

- **NCT ID:** NCT00050401
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 500 (—)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050401, "Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00050401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*